Last edition
News about Market
Zealand Pharma Signs USD 100 Million Royalty Deal with Royalty Pharma for Rusfertide
Zealand Pharma will receive USD 100 million from Royalty Pharma for its rusfertide economic interests, unlocking value from royalty rights for strategic investments.
Market | 13/08/2026 | By News Bureau | 173
CellProthera and Alfresa Sign MOU to Advance ProtheraCytes Phase 3 in Japan
CellProthera and Alfresa Holdings have signed a Memorandum of Understanding (MOU) to advance ProtheraCytes phase 3 development and future wholesale distribution in Japan for severe myocardial infarction.
Market | 13/08/2026 | By News Bureau | 138
Sentynl and Mereo Partner on Alvelestat for AATD-Associated Lung Disease
Sentynl Therapeutics and Mereo BioPharma have signed an option and license deal for alvelestat, with Sentynl set to commercialise it in the US upon option exercise.
Market | 12/08/2026 | By News Bureau | 103
Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for USD 820 million upfront and up to USD 500 million in contingent payments, expanding its rare epilepsy pipeline with investigational therapy ABS-1230.
Market | 12/08/2026 | By News Bureau | 128
Boehringer Ingelheim Acquires Swiss Biotech Evax to Advance Therapeutic Vaccines for Equine Health
Boehringer Ingelheim has acquired Swiss biotech Evax AG to advance virus-like particle-based therapeutic vaccines aimed at addressing allergic skin diseases and other unmet health needs in horses.
Market | 12/08/2026 | By News Bureau | 115
Amneal Completes Kashiv BioSciences Acquisition to Strengthen Biosimilars Business
Amneal has completed its acquisition of Kashiv BioSciences, creating an integrated global biosimilar platform spanning R&D, manufacturing and commercialisation.
Market | 11/08/2026 | By News Bureau | 108
Gland Pharma Announces Strategic CDMO Partnership with Global Pharmaceutical Company
Gland Pharma has partnered with a global pharmaceutical company to provide end-to-end Contract Development and Manufacturing Organisation (CDMO) services across commercial and pipeline products throughout their lifecycle.
Market | 11/08/2026 | By News Bureau | 136
Akums Drugs and Pharmaceuticals Reports 35.4 Percent EBITDA Growth in Q1 FY27
Akums Drugs and Pharmaceuticals starts FY27 on a strong note, reporting robust revenue, EBITDA and PAT growth as its CDMO business continues to drive performance.
Market | 11/08/2026 | By News Bureau
Zydus Launches REVAHALE, India's First Once-Daily Nebulised LAMA for COPD
Zydus launches REVAHALE (revefenacin), India’s first once-daily nebulised LAMA for COPD, offering sustained 24-hour bronchodilation through nebulised delivery.
Market | 11/08/2026 | By News Bureau
Innate Pharma Partners with Sobi to License Lacutamab in T-cell Lymphoma
Innate Pharma and Sobi have partnered to advance lacutamab in T-cell lymphoma, with Innate leading the TELLOMAK-3 phase 3 trial in CTCL.
Market | 11/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy